Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Malaysia.
Faculty of Pharmacy, Lincoln University College, Kuala Lumpur, Malaysia.
Diabetes Res Clin Pract. 2018 Feb;136:52-77. doi: 10.1016/j.diabres.2017.11.018. Epub 2017 Nov 28.
Nanotechnology science has been diverged its application in several fields with the advantages to operate with nanometric range of objects. Emerging field of nanotechnology has been also being approached and applied in medical biology for improved efficacy and safety. Increased success in therapeutic field has focused several approaches in the treatment of the common metabolic disorder, diabetes. The development of nanocarriers for improved delivery of different oral hypoglycemic agents compared to conventional therapies includes nanoparticles (NPs), liposomes, dendrimer, niosomes and micelles, which produces great control over the increased blood glucose level and thus becoming an eye catching and most promising technology now-a-days. Besides, embellishment of nanocarriers with several ligands makes it more targeted delivery with the protection of entrapped hypoglycaemic agents against degradation, thereby optimizing prolonged blood glucose lowering effect. Thus, nanocarriers of hypoglycemic agents provide the aim towards improved diabetes management with minimized risk of acute and chronic complications. In this review, we provide an overview on distinctive features of each nano-based drug delivery system for diabetic treatment and current NPs applications in diabetes management.
纳米科技因其能在纳米范围内操作物体的优势，已经在多个领域得到了应用。新兴的纳米技术领域也已经在医学生物学中得到了应用，以提高疗效和安全性。在治疗常见代谢紊乱疾病糖尿病方面的治疗取得了更多的成功，这集中在几种方法上。与传统疗法相比，纳米载体的开发可改善不同口服降血糖药物的递送，包括纳米粒子（NPs）、脂质体、树枝状大分子、囊泡和胶束，这对控制血糖升高产生了很大的影响，因此成为当今引人注目的最有前途的技术。此外，通过用几种配体修饰纳米载体，可以实现更有针对性的递送，并保护包封的降血糖剂免受降解，从而优化延长的降血糖效果。因此，纳米载体的降血糖剂为改善糖尿病管理提供了目标，同时最大限度地降低了急性和慢性并发症的风险。在这篇综述中，我们概述了每种基于纳米的药物传递系统用于糖尿病治疗的独特特征，以及目前纳米粒子在糖尿病管理中的应用。
